Novel Ingredients Featured at VitaFoods Europe 2022
Tacoma, WA – June 10, 2022 – Unigen Inc., showcased its branded ingredient offerings at the recent Vitafoods Europe 2022 in Geneva. Vitafoods Europe is considered the world’s most attended nutraceutical event, attracting over 25,000 industry experts and 1000 + exhibiting brands from over 135 countries.
Unigen exhibited in the US Pavilion and also featured its corporate services and novel ingredients on Vitafoods Europe’s virtual site. Unigen’s featured products included Anivestin™, AmLexin®, Attenutin™, Loesyn™, Symetrian™, and Univestin®. Also highlighted was Unigen’s propriety discovery technology, Phytologix®, one of the world’s largest information sources for predictive discovery of ethnomedicinal plants.
Unigen’s CEO, Dr. Qi Jia, PhD, also presented the company’s newest immune/respiratory ingredients Attenutin™ and Symetrian™ at the New Ingredients Theater. Attenutin™ is a standardized bioflavonoid composition from roots of Scutellaria baicalensis and heartwoods of Acacia catechu; Symetrian™ is a standardized polysaccharide & polyphenol composition from Aloe vera gel powder, Poria cocos sclerotium extract and Rosemary leaf extracts.
Attenutin™ is clinically proven to maintain a healthy level of HMGB1 for protecting immune function of the respiratory system. Symetrian™ is clinically proven to promote production of circulating Gamma delta T cells suggesting its heightened immune surveillance at portal of entries.
“This is the first time Unigen has exhibited at Vitafoods Europe,” Dr. Jia noted. “In addition to presenting in the New Ingredients Theater, we engaged with more than 20 distributors at the show who expressed strong interest in our scientifically substantiated, clinically proven, and patented ingredients. There are significant business opportunities in Europe to promote Unigen’s trademarked ingredients. We are very excited to enter the European market,” said Dr. Jia.
Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food, and botanical drug products. The Company discovers its ingredients through its high throughput screening Phytologix® platform applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. The mechanism of action, safety, and efficacy is documented with extensive pre-clinical in vitro and in vivo testing and human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacturing, distributing, and marketing of end products in each of Unigen’s target markets.